Group 1 - The China Securities Regulatory Commission (CSRC) has announced supplementary material requirements for 23 companies regarding their overseas issuance and listing [1][2][3] - Specific companies such as Huafu Technology and Shanjin International have been highlighted for particular concerns regarding shareholder relationships and safety production incidents [1][2][3] - The supplementary materials are aimed at ensuring compliance with regulations and addressing potential issues that may affect the companies' ability to list [1][2][3] Group 2 - Companies like Shichuang Securities and Zhineng Technology are required to clarify the status of state-owned shareholder identification and trust arrangements [2][3] - For Xiangdao Travel, there are inquiries about the actual operations of various services and whether necessary qualifications have been obtained [2][3] - Bo Rui Pharmaceutical is asked to provide details on its business operations related to health food sales and medical research, including necessary licenses [2][3] Group 3 - Guoxin Services must explain the status of significant litigation cases and their potential impact on future operations and the current issuance [3][4] - Hi Learning Network is required to clarify compliance with labor and social insurance regulations, as well as the status of pending lawsuits and administrative penalties [4][5] - Tian Nong Group needs to address compliance issues regarding animal husbandry licenses and environmental permits, which may pose significant legal risks [5][6] Group 4 - Companies like Fengjiang Management and Mingyu Pharmaceutical are required to provide legal opinions on their compliance with foreign investment regulations and the legitimacy of their capital structures [7][8][9] - Specific inquiries include the legitimacy of shareholding structures and the compliance of fundraising activities with regulatory requirements [7][8][9] - The focus is on ensuring that all companies meet the necessary legal and regulatory standards for their overseas listings [7][8][9]

证券代码：688166 证券简称：博瑞医药 公告编号：2026-002 转债代码：118004 转债简称：博瑞转债 博瑞生物医药（苏州）股份有限公司 关于不提前赎回"博瑞转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 自 2025 年 12 月 12 日至 2026 年 1 月 5 日，博瑞生物医药（苏州）股份 有限公司（以下简称"公司"）股票满足连续 30 个交易日中有 15 个交易日收盘 价格不低于当期转股价格的 130%（即 45.16 元/股），已触发《博瑞生物医药（苏 州）股份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简称"可 转债募集说明书"）中规定的有条件赎回条款。 公司于 2026 年 1 月 5 日召开第四届董事会第十七次会议，审议通过《关 于不提前赎回"博瑞转债"的议案》，决定本次不行使"博瑞转债"的提前赎回 权利，不提前赎回"博瑞转债"。 未来三个月内（即 2026 年 1 月 6 日至 2026 年 4 月 5 日期间），如"博瑞 转债"再次触发有条件赎回 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2026-001 转债代码：118004 转债简称：博瑞转债 博瑞生物医药（苏州）股份有限公司 可转债转股结果暨股份变动公告 未转股可转债情况：截至 2025 年 12 月 31 日，"博瑞转债"尚未转股的 可转债金额为 442,766,000 元，占"博瑞转债"发行总量的 95.2185%。 一、可转债发行上市概况 经中国证券监督管理委员会证监许可[2021]3551 号文同意注册，博瑞生物医 药（苏州）股份有限公司（以下简称"公司"）于 2022 年 1 月 4 日向不特定对 象发行 465 万张可转换公司债券，每张面值为人民币 100 元，发行总额 46,500.00 万元。本次发行的可转换公司债券的期限为自发行之日起六年，即 2022 年 1 月 4 日至 2028 年 1 月 3 日。 经上海证券交易所自律监管决定书[2022]22 号文同意，公司 46,500.00 万元 可转换公司债券于 2022 年 1 月 27 日起在上海证券交易所挂牌交易，债券简称"博 瑞转债"，债券代码"118004"。 根据有关规定和《博瑞生物医药（苏州）股份有限公 ...

国联民生承销保荐有限公司 关于博瑞生物医药（苏州）股份有限公司 不提前赎回"博瑞转债"的核查意见 国联民生承销保荐有限公司（以下简称"国联民生承销保荐"或"保荐机构"） 作为博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"、"公司"或"发 行人"）向不特定对象发行可转换公司债券的保荐机构，根据《证券发行上市保 荐业务管理办法》《上海证券交易所上市公司自律监管指引第1号——规范运作》 《上海证券交易所上市公司自律监管指引第11号——持续督导》及《上海证券 交易所上市公司自律监管指引第12号——可转换公司债券》等有关规定，对博 瑞医药本次不提前赎回"博瑞转债"的事项进行了审慎核查，核查情况及核查意 见如下： 一、可转债的发行上市情况 经中国证券监督管理委员会《关于同意博瑞生物医药（苏州）股份有限公司 向不特定对象发行可转换公司债券注册的批复》（证监许可[2021]3551号）同意 注册，公司向不特定对象共计发行465万张可转换公司债券，每张面值为人民币 100元，按面值发行。本次发行合计募集资金人民币465,000,000元，扣除不含税 的发行费用人民币8,168,820.75元后，募集资金净额为人民币45 ...

Core Viewpoint - The company, Borui Pharmaceutical, has announced a delay in the expected completion dates for several fundraising investment projects, pushing them to March 2027 due to regulatory approval processes and additional construction needs [2][3]. Trading Information Summary - On December 31, 2025, Borui Pharmaceutical's stock closed at 49.06 yuan, down 0.69%, with a turnover rate of 0.89% and a trading volume of 37,800 shares, amounting to a total transaction value of 186 million yuan [1]. - The net outflow of main funds was 11.73 million yuan, accounting for 6.32% of the total transaction value, while retail investors saw a net inflow of 5.07 million yuan, representing 2.73% of the total [2]. Company Announcement Summary - The Board of Directors approved a proposal to delay the expected completion dates for several fundraising investment projects to March 2027, which include the construction of an inhalation and chemical drug production base and a biopharmaceutical research center [2][3]. - The delay is attributed to products being in the approval stage and the need for additional construction of an automated warehouse, which requires synchronized acceptance [2][3]. - The delay does not change the intended use of the raised funds and does not affect the company's normal operations [2][3]. Internal Governance and Management Systems - The company has established an internal audit management system to ensure independent auditing of internal controls, financial information, and operational activities [4]. - A foreign exchange transaction management system has been implemented to mitigate exchange rate risks and ensure fund security, prohibiting speculative activities [5]. - The company has also set up a fundraising management method to regulate the use and supervision of raised funds, ensuring they are used exclusively for designated projects [6]. - A management system for shares held by directors and senior management has been created to regulate share transactions and disclosures [7].

Core Viewpoint - 博瑞医药 has experienced a stock price increase and has announced a delay in several fundraising projects, which will not affect the company's normal operations or the intended use of funds [1][2][3]. Group 1: Stock Performance - As of December 26, 2025, 博瑞医药's stock closed at 50.21 yuan, up 3.31% from the previous week [1]. - The stock reached a high of 50.97 yuan and a low of 48.22 yuan during the week [1]. - The company's total market capitalization is 20.757 billion yuan, ranking 22nd in the chemical pharmaceutical sector and 947th among all A-shares [1]. Group 2: Company Announcements - 国联民生证券 conducted a site inspection for 博瑞医药's 2025 annual continuous supervision, finding no violations in governance, information disclosure, or major investments [2][6]. - 博瑞医药's board approved a resolution to postpone the expected operational status date for several fundraising projects to March 2027 due to pending product approvals and the addition of an automated warehouse [2][3]. - The delay affects projects including the inhalation and chemical drug formulation production base and the biopharmaceutical R&D center [2][3]. Group 3: Internal Governance - 博瑞医药 has established an internal audit system to oversee internal controls, financial information, and operational activities [4]. - The company has implemented a management system for forward foreign exchange transactions to mitigate exchange rate risks [4]. - A fundraising management method has been developed to ensure that raised funds are used specifically for intended projects and are subject to strict oversight [5][6]. Group 4: Management Regulations - 博瑞医药 has set up a management system for shares held by directors and senior management, regulating trading periods and disclosure requirements [7].

截至2025年12月30日收盘，博瑞医药(688166)报收于49.4元，下跌0.66%，换手率0.98%，成交量4.14万 手，成交额2.05亿元。 当日关注点 交易信息汇总 第四届董事会第十六次会议决议公告 博瑞医药第四届董事会第十六次会议于2025年12月29日召开，审议通过《关于募集资金投资项目延期的 议案》，将多个募投项目达到预定可使用状态时间延期至2027年3月。同时审议通过修订及制定公司部 分内部治理制度的议案，涉及累积投票制、独立董事制度、董事会各专门委员会工作制度、募集资金使 用管理、对外担保、对外投资、内幕信息管理等多项制度。所有议案均获全票通过。 内部审计管理制度（2025年12月） 博瑞生物医药（苏州）股份有限公司制定内部审计制度，明确内部审计机构在审计委员会领导下独立开 展工作，负责对公司及下属单位的内部控制、财务信息、经营活动等进行审计监督。制度规定了内部审 计的职责、权限、工作程序及审计范围，包括内部控制审计、运营审计、合规审计、舞弊审计、经济责 任审计、专项审计和信息系统审计等。内部审计机构需定期向审计委员会报告，并对发现问题的整改情 况进行跟踪。公司对审计人员履职予以保障，严 ...

博瑞生物医药（苏州）股份有限公司 内部审计制度 一、总则 第一条 为了规范博瑞生物医药（苏州）股份有限公司（以下简称"公司"） 内部审计工作，充分发挥内部审计的监督管理职能，提高企业管理水平，加强 公司内部控制，根据《中华人民共和国审计法》、《中华人民共和国审计署关 于内部审计工作的规定》、《上海证券交易所股票科创板上市规则》等法律、 法规、规范性文件及《博瑞生物医药（苏州）股份有限公司章程》（以下简称 "公司章程"）的规定，结合公司实际情况，制定本制度。 第二条 本制度所称内部审计，是指公司内部审计机构或人员，对公司内部 控制和风险管理的有效性、财务信息的真实性和完整性以及经营活动的效率和 效果等开展的审查与评价活动。 第三条 本制度适用于公司及下属各部门、分公司、控股子公司以及公司能 够对其实施重大影响的参股公司(以下简称"参股公司")。 二、内部审计机构设置和人员配备 第四条 公司在董事会下设审计委员会，内部审计机构为公司审计委员会专 门工作机构，负责公司内部审计及内部控制相关工作，配备与公司规模以及工 作量相匹配的专职工作人员，在审计委员会领导下独立开展内部审计工作。必 要时经批准可聘请外部人员或审计 ...

Group 1 - The company, Borui Pharmaceutical, announced that its fourth board meeting was held on December 29, 2025, to discuss the proposal regarding the extension of fundraising investment projects [1] - The meeting took place in the C27 conference room [1]

博瑞生物医药（苏州）股份有限公司 第一条 为规范博瑞生物医药（苏州）股份有限公司（以下简称"公司"）远 期外汇交易业务及相关信息披露工作，加强对远期外汇交易业务的管理，防范汇 率风险，保证公司资金安全，根据《中华人民共和国公司法》、《中华人民共和国 证券法》、《上海证券交易所科创板股票上市规则》等法律、法规和规范性文件， 以及《公司章程》等有关规定，结合公司实际情况，制定本制度。 第二条 本制度所称远期外汇交易特指在银行等金融机构办理的规避和防范 汇率风险的远期外汇交易业务，包括远期结售汇业务、人民币外汇掉期业务等低 风险外汇交易。 远期结售汇业务是指与银行等金融机构签订远期结售汇合同，约定将来办理 结汇或售汇的外汇币种、金额、汇率和期限，到期再按照该远期结售汇合同约定 的币种、金额、汇率办理结汇或售汇的业务。 人民币外汇掉期业务是指在委托日同时与银行等金融机构约定两笔金额一 致、买卖方向相反、交割日期不同的人民币对同一外币的买卖交易，并在两笔交 易的交割日按照该掉期合约约定的币种、金额、汇率办理的结汇或售汇业务。 第三条 公司从事远期外汇交易业务应遵守国家有关法律、法规、规范性文 件的规定，还应遵守本制度的 ...